Rheumatoid Arthritis (RA) is a chronic inflammatory disorder that affects joints, causing pain, swelling, and stiffness. Managing RA involves a variety of treatment options, including disease-modifying antirheumatic drugs (DMARDs). Xeljanz (tofacitinib) and Rinvoq (upadacitinib) are two oral DMARDs that have gained popularity in recent years. This blog post aims to provide a comparative analysis of Xeljanz and Rinvoq to help individuals and healthcare professionals make informed decisions regarding RA treatment.